We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Arrowhead Nanobiotechnology Subisidaries, Calando and Insert Complete Merger
News

Arrowhead Nanobiotechnology Subisidaries, Calando and Insert Complete Merger

Arrowhead Nanobiotechnology Subisidaries, Calando and Insert Complete Merger
News

Arrowhead Nanobiotechnology Subisidaries, Calando and Insert Complete Merger

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Arrowhead Nanobiotechnology Subisidaries, Calando and Insert Complete Merger"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Arrowhead Research Corporation has announced the completion of the merger between Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc. The merger is part of a streamlining of the two companies in which Arrowhead assumed active management to increase efficiency and focus resources on bringing multiple products to the clinic as rapidly as possible. The merged company will do business under the name "Calando Pharmaceuticals, Inc."

"Both Calando and Insert are on track to maximize value from their core technologies and each has recently announced progress toward additional clinical trials," said Christopher Anzalone, Arrowhead's CEO. "The companies are built around very similar platforms and we saw compelling reasons to merge them into a single, more efficient entity. We believe the result will be a leaner and stronger company going forward with multiple compounds in clinical development."

Calando has an active clinical program that spans small molecule and siRNA therapeutics for the treatment of cancer. Calando's IT-101 compound is moving into phase II clinical trials for the treatment of ovarian cancer. Calando's CALAA-01 has been cleared by the FDA to begin phase I clinical trials and is on track to be the first use of siRNA for the treatment of cancer in humans.

Advertisement